HYDROXYUREA

Search structure
Trade Names:
Synonyms:
Status: Approved (1967)
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: X6Q56QN5QC

Structure
InChI Key VSNHCAURESNICA-UHFFFAOYSA-N
Smile NC(=O)NO
InChI
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

Physicochemical Descriptors

Property Name Value
Molecular Formula CH4N2O2
Molecular Weight 76.05
AlogP -0.96
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 0.0
Polar Surface Area 75.35
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 5.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Ribonucleoside-diphosphate reductase RR1 inhibitor PubMed DailyMed
Primary Target
ribonucleotide reductase catalytic subunit M1
ribonucleotide reductase regulatory subunit M2
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Lyase
- - - 23000 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 113

Metabolites

visNetwork

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Carcinoma 3 D002277 ClinicalTrials
Laryngeal Neoplasms 3 D007822 ClinicalTrials
Paranasal Sinus Neoplasms 3 D010255 ClinicalTrials
Glioblastoma 3 D005909 ClinicalTrials
Pharyngeal Neoplasms 3 D010610 ClinicalTrials
Hemochromatosis 3 D006432 ClinicalTrials
Primary Myelofibrosis 3 D055728 ClinicalTrials
Polycythemia Vera 3 D011087 ClinicalTrials
Stroke 3 D020521 ClinicalTrials
HIV Infections 3 D015658 ClinicalTrials
Primary Myelofibrosis 3 D055728 ClinicalTrials
Myelodysplastic Syndromes 3 D009190 ClinicalTrials
Thrombocythemia, Essential 3 D013920 ClinicalTrials
Mouth Neoplasms 3 D009062 ClinicalTrials
Myeloproliferative Disorders 3 D009196 ClinicalTrials
Hematologic Diseases 3 D006402 ClinicalTrials
Leukemia, Promyelocytic, Acute 3 D015473 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Fibromatosis, Aggressive 2 D018222 ClinicalTrials
Multiple Sclerosis 2 D009103 ClinicalTrials
beta-Thalassemia 2 D017086 ClinicalTrials
Meningioma 2 D008579 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Gliosarcoma 2 D018316 ClinicalTrials
Hemoglobin SC Disease 2 D006450 ClinicalTrials
beta-Thalassemia 2 D017086 ClinicalTrials
Muscular Atrophy, Spinal 2 D009134 ClinicalTrials
Central Nervous System Neoplasms 2 D016543 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Esophageal Neoplasms 2 D004938 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Lung Neoplasms 1 D008175 ClinicalTrials
Hypertension, Pulmonary 0 D006976 ClinicalTrials

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
8.8
Skin and subcutaneous tissue disorders
8.04
Injury, poisoning and procedural complications
7.96
Investigations
7.53
Blood and lymphatic system disorders
7.4
Gastrointestinal disorders
7.38
Vascular disorders
7.34
Respiratory, thoracic and mediastinal disorders
6.44
Nervous system disorders
5.18
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.89
Infections and infestations
4.64
Musculoskeletal and connective tissue disorders
3.77
Cardiac disorders
3.17
Metabolism and nutrition disorders
2.6
Immune system disorders
2.51
Surgical and medical procedures
2.44

Cross References

Resources Reference
CAS NUMBER 127-07-1
ChEBI 44423
ChEMBL CHEMBL467
DrugBank DB01005
DrugCentral 1399
EPA CompTox DTXSID6025438
FDA SRS X6Q56QN5QC
Human Metabolome Database HMDB0015140
Guide to Pharmacology 6822
KEGG C07044
PDB NHY
PharmGKB PA449942
PubChem 3657
SureChEMBL SCHEMBL4004
ZINC ZINC000008034120
CONTENTS